DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Symptomatic Treatment of Acute Gastroenteritis

Information source: IRCCS Burlo Garofolo
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Gastroenteritis; Vomiting; Acute Gastroenteritis

Intervention: Ondansetron (Drug); Domperidone (Drug); placebo (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: IRCCS Burlo Garofolo

Official(s) and/or principal investigator(s):
Federico Marchetti, MD, Study Chair, Affiliation: IRCCS Burlo Garofolo
Maurizio Bonati, MD, Study Director, Affiliation: Mario Negri Institute for Pharmacological Research

Overall contact:
Luca Ronfani, MD, PhD, Phone: 0039/040/3785, Ext: 401, Email: ronfani@burlo.trieste.it

Summary

Vomiting in children with acute gastroenteritis is a major factor of failure of oral rehydration therapy. Effective symptomatic treatment of vomiting would lead to an important reduction in the use of Intravenous Fluid Therapy. Available evidence on symptomatic treatment of vomiting shows the efficacy of the most recently registered molecule (ondansetron) but a proper evaluation of antiemetics drugs largely used in clinical practice, such as domperidone, is lacking.

The aim of this multicentre, double-blind randomized controlled trial is to compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with acute gastroenteritis who have failed Oral Rehydration Therapy.

Clinical Details

Official title: Oral Ondansetron vs Domperidone for Symptomatic Treatment of Vomiting During Acute Gastroenteritis in Children: Multicentre Randomized Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Percentage of patients needing nasogastric or intravenous rehydration after symptomatic oral treatment failure, defined as vomiting or fluid refusal after the second attempt of ORT.

Secondary outcome:

Percentage of subjects needing hospital admission for the same illness;

Percentage of subjects needing observation stay for more than 6 hours for the same illness

Total emesis duration in the 3 allocation groups;

Number of episodes of vomiting in the 3 treatment groups during the follow-up period

Percentage of subjects presenting adverse events

Detailed description: Vomiting in children with acute gastroenteritis (AG) is not only a direct cause of fluid loss but it is also a major factor of failure of oral rehydration therapy (ORT). Physicians who provide care to paediatric patients in the emergency department (ED) usually prescribe intravenous fluid therapy (IVT) for mild or moderate dehydration when vomiting is the major symptom. Thus, effective symptomatic treatment of vomiting would lead to an important reduction in the use of IVT and, consequently, of the duration of hospital stay and of frequency of hospital admission. Available evidence on symptomatic treatment of vomiting shows the efficacy of the most recently registered molecule (ondansetron) but a proper evaluation of antiemetics drugs largely used in clinical practice, such as domperidone, is lacking.

The aim of this multicentre, double-blind randomized controlled trial conducted in paediatric Emergency Departments is to compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with AG who have failed Oral Rehydration Therapy.

The trial results would provide evidence on the efficacy of domperidone, which is largely used in clinical practice despite the lack of proper evaluation and a controversial safety profile, as compared to ondansetron, which is not yet authorized in Italy despite evidence supporting its efficacy in treating vomiting. The trial results would contribute to a reduction in the use of IVT and, consequently, in hospital admissions in children with AG. The design of this RCT, which closely reflect current clinical practice in EDs, will allow immediate transferability of results

Eligibility

Minimum age: 1 Year. Maximum age: 6 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. age from 1 to 6 years;

2. presumptive clinical diagnosis of acute gastroenteritis in patients with vomiting, with or without diarrhoea;

3. more than three episodes of non-bilious, non-bloody vomiting within the previous 24 hours;

Exclusion Criteria:

1. treatment with antiemetics or antidiarrhoic drugs in the 6 hours prior to access to ED;

2. underlying chronic diseases (eg, malignancy, gastroesophageal reflux, migraine, renal failure, hypoalbuminemia, liver disease);

3. severe dehydration: weight loss>10% or standardized clinical dehydration score >=18 for children aged 12-24 months and >=16 for older children;

4. known hypersensitivity to ondansetron or domperidone;

5. previous enrolment in the study.

Locations and Contacts

Luca Ronfani, MD, PhD, Phone: 0039/040/3785, Ext: 401, Email: ronfani@burlo.trieste.it

Dipartimento di Emergenza Pediatrica, Ospedale Giuseppe Moscati, Avellino, Italy; Recruiting
Antonio Vitale, MD, Principal Investigator

Dipartimento di Emergenza Pediatrica, P.O. Spedali Civili, Brescia, Italy; Recruiting
Alberto Arrighini, MD, Principal Investigator

Divisione di Emergenza Pediatrica, Ospedale Pediatrico A. Meyer, Firenze, Italy; Recruiting
Francesco Mannelli, MD, Principal Investigator
Anna Pazzaglia, MD, Sub-Investigator

Unità Operativa di Pediatria, Ospedale GB Morgagni, Forlì, Italy; Recruiting
Enrico Valletta, MD, Principal Investigator

Divisione di Emergenza Pediatrica, Istituto G. Gaslini, Genova, Italy; Recruiting
Pasquale Di Pietro, MD, Principal Investigator
Salvatore Renna, MD, Sub-Investigator

Dipartimento di Pediatrica, Ospedale di Macerata, Macerata, Italy; Recruiting
Paolo Francesco Perri, MD, Principal Investigator

Dipartimento di Pediatria, Azienda Policlinico di Modena, Modena, Italy; Recruiting
Paolo Bertolani, MD, Principal Investigator

Dipartimento di Emergenza Pediatrica, Azienda Ospedaliera - Università di Padova, Padova, Italy; Recruiting
Tiziana Zangardi, MD, Principal Investigator

Dipartimento di Pediatrica, Azienda Ospedaliera- Università di Parma, Parma, Italy; Recruiting
Maria Teresa Tondelli, MD, Principal Investigator

Dipartimento di Emergenza Pediatrica, Ospedale Pediatrico IRCCS Bambino Gesú, Roma, Italy; Recruiting
Antonino Reale, MD, Principal Investigator

Dipartimento di Emergenza Pediatrica, Ospedale Infantile Regina Margherita, Torino, Italy; Recruiting
Antonio Francesco Urbino, MD, Principal Investigator

Dipartimento di Pediatria, Ospedale di Treviso, Treviso, Italy; Recruiting
Liviana Da Dalt, MD, Principal Investigator

Dipartimento di Emergenza Pediatrica, Istituto per la l'Infanzia, IRCCS Burlo Garofolo, Trieste, Italy; Recruiting
Gianni Messi, MD, Principal Investigator
Egidio Barbi, MD, Principal Investigator
Lorenzo Calligaris, MD, Sub-Investigator

Unità di Terapia Intensiva Pediatrica, Ospedale Civile Maggiore, Verona, Italy; Recruiting
Paolo Biban, MD, Principal Investigator

Dipartimento di Pediatria, Ospedale Castelli, Verbania, Novara, Italy; Recruiting
Andrea Guala, MD, Principal Investigator

Additional Information

Related publications:

Marchetti F, Maestro A, Rovere F, Zanon D, Arrighini A, Bertolani P, Biban P, Da Dalt L, Di Pietro P, Renna S, Guala A, Mannelli F, Pazzaglia A, Messi G, Perri F, Reale A, Urbino AF, Valletta E, Vitale A, Zangardi T, Tondelli MT, Clavenna A, Bonati M, Ronfani L. Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial. BMC Pediatr. 2011 Feb 10;11:15.

Starting date: July 2011
Last updated: August 31, 2011

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014